BiotechTube

Momelotinib (MMB) + Trametinib

Phase 1Terminated
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

Conditions

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

Trial Timeline

Mar 11, 2015 → Feb 27, 2017

NCT ID
NCT02258607

About Momelotinib (MMB) + Trametinib

Momelotinib (MMB) + Trametinib is a phase 1 stage product being developed by GSK plc for Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02258607. Target conditions include Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02258607Phase 1Terminated

Competing Products

20 competing products in Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
agenT-797MiNK TherapeuticsPhase 1
25
VIP152 + BTKiVincerx PharmaPhase 1
25
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
77
AC220Daiichi SankyoPhase 1
33
Valemetostat TosylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
AGS67EAstellas PharmaPhase 1
33
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
41
LenvatinibEisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
Eribulin mesylateEisaiPhase 2
52
ME-401Kyowa KirinPhase 1
33
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6Kyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
ONO-4685Ono PharmaceuticalPhase 1
33
ONO-4685Ono PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77

Other Products from GSK plc

KetoconazoleApproved
84
Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene + clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazaroteneApproved
84
Duac® Gel / Differin® GelApproved
84
Acitretin (also called U0279) + Placebo + EtanerceptApproved
84
Epiduo Gel + Duac GelApproved
84